SCHEMBL2184451

SCHEMBL2184451

O=C1NN(c2ccc(Cl)c(Cl)c2)C(=O)/C1=C\c1ccc(Cl)c([N+](=O)[O-])c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 8/20 0.84
KMT2A Q03164 10/20 0.69
MEN1 O00255 9/20 0.69
POLB P06746 8/20 0.69
GAA P10253 6/20 0.69
GFER P55789 2/20 0.69
GALK1 P51570 1/20 0.69
HKDC1 Q2TB90 1/20 0.69
MAPT P10636 7/20 0.59
ATM Q13315 1/20 0.59
CTDSP1 Q9GZU7 1/20 0.59
ABL1 P00519 2/20 0.53
SRC P12931 2/20 0.53
ALDH1A1 P00352 6/20 0.51
HTT P42858 1/20 0.51
RECQL P46063 2/20 0.49
HPGD P15428 2/20 0.49
MCL1 Q07820 2/20 0.49
ALOX12 P18054 1/20 0.49
TDP1 Q9NUW8 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2184453 1.00 DYRK1A (0.84) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL28302105 0.91 DYRK1A (1.00) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL3760714 0.82 DYRK1A (1.00) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL3760715 0.82 DYRK1A (1.00) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL3760719 0.82 DYRK1A (1.00) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL2185916 0.79 KMT2A (0.70) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL2185917 0.79 KMT2A (0.70) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL18841380 0.77 DYRK1A (0.75) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL18841378 0.76 DYRK1A (0.74) DYRK1AKMT2AMEN1POLBGAA
SCHEMBL18841384 0.76 DYRK1A (0.74) DYRK1AKMT2AMEN1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9949980-B2 Drugs to prevent HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2018-04-24 US disclosed
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 US disclosed
US-9066951-B2 Drugs to treat HPV infection WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-06-30 US disclosed
US-20110165220-A1 DRUGS TO PREVENT HPV INFECTION WISCONSIN ALUMNI RESEARCH FOUNDATION 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165220-A1 DRUGS TO PREVENT HPV INFECTION VHL, PHF13, CDKN1A DYRK1A 2075/4885KMT2A 400/4885MEN1 1211/4885
US-20150297602-A1 DRUGS TO PREVENT HPV INFECTION VHL, PHF13, CDKN1A DYRK1A 2075/4885KMT2A 400/4885MEN1 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.